Finding ways to correct ApoE4 for treating Alzheimer's Disease
Discovery and optimization of ApoE4 correctors for the treatment of Alzheimer's Disease
This study is looking for new ways to help people with a gene that raises their risk of Alzheimer's by creating small molecules that can fix a protein called ApoE4, making it work better like the safer version, ApoE3.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sanford Burnham Prebys Medical Discovery Institute NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10860579 on NIH RePORTER |
What this research studies
This research focuses on developing small molecules that can modify the ApoE4 protein, which is linked to a significantly increased risk of Alzheimer's Disease. By understanding the structural differences between ApoE4 and the more protective ApoE3, the team aims to create 'correctors' that can help restore the function of ApoE4. The approach involves purifying the ApoE4 protein and assessing its stability and functionality through various assays. Patients with a genetic predisposition to Alzheimer's may benefit from these advancements in treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who carry the ApoE4 allele and are at risk for developing Alzheimer's Disease.
Not a fit: Patients who do not carry the ApoE4 allele may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options that significantly reduce the risk or progression of Alzheimer's Disease in patients with the ApoE4 allele.
How similar studies have performed: While there have been attempts to target ApoE4 in the past, this specific approach of developing correctors is novel and has not yet been widely tested.
Where this research is happening
La Jolla, United States
- Sanford Burnham Prebys Medical Discovery Institute — La Jolla, United States (Active)
Researchers
- Principal investigator: Jackson, Michael — Sanford Burnham Prebys Medical Discovery Institute
- Study coordinator: Jackson, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.